Search

News: Pherecydes Pharma announces the first international approval of a compassionate treatment with its phages.

Adaptive Phage Therapeutics announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a Phase 1/2 clinical study to evaluate the safety and efficacy of APT’s precision phage therapy in patient

Armata Pharmaceuticals announces first patient dosed in phase 1b/2a 'diSArm' study of AP-SA02 in adults with bacteremia due to Staphylococcus aureus.

Intralytix has been granted FDA clearance for an investigational new drug application for phase 1/2a clinical trials for vancomycin resistant Enterococci (VRE)-targeting phage.

Funding: The AMR Action fund has invested $20 million in Adaptive Phage Therapeutics. Congrats APT!

ACD Pharma is constructing a large-scale phage production plant.

The CF Foundation has awarded $5 Million to BiomX to conduct a Phase 1b/2a clinical trial to test the safety and tolerability of phage therapy for Pseudomonas aeruginosa infections in people with cystic fibrosis.

Microbiome Times analysed its Microbiome Drug Database™, a repository of biotechs developing microbiome drugs, for phage-related drugs. They found that almost 70% of the total of 100 company-sponsored, phage-based drug development programs

Royal DSM, a Dutch nutrition, health and bioscience company, has released a one-hour phage testing kit

TechnoPhage announces first clinical safety results with their phage cocktail, TP-102, now advancing to phase 2. TP-102 is assessed for its safety and tolerability in individuals with diabetic foot ulcers, and showed no adverse effects in t

Adaptive Phage Therapeutics announced a strategic agreement with the Antibacterial Resistance Leadership Group to support a phase 1b/2 cystic fibrosis (CF) study. The randomized, double-blind, placebo-controlled trial will assess the safety

Adaptive Phage Therapeutics was awarded an additional $8 Million from the U.S. Department of Defense (DoD) for the continued development of phage therapies for the treatment of infectious diseases. The new funding brings the total DoD contr

Felix Biotechnology was awarded an NSF Small Business Innovation Research (SBIR) Phase I grant for $256,000 to further enhance their machine learning-based approach for engineering phage as a novel treatment for drug-resistant bacterial inf

Adaptive Phage Therapeutics (APT) has signed a licensing agreement with the Walter Reed Army Institute of Research to gain access to its phage database. The deal is synergistic with APT's ongoing partnership with the US Navy.

US phage biotech company Intralytix received a Fast Track NIH SBIR contract to develop a universal, scale-independent AI-based platform for manufacturing high titer phage preparations for clinical applications. Intralytix will receive a Pha

Proteon Pharmaceuticals announced an investment of 21 million Euro to accelerate commercialization of its phage products, which aim to reduce reliance on antibiotics in aquaculture and livestock farming, improve on-farm performance and incr

Biochimpharm, a Georgian phage biotech company, has been awarded a $150,000 grant from the EU and the United Nations FAO to support production of PowerPhage, a phage cocktail product that targets Salmonella, E. coli and Shigella, for veteri

Felix Biotechnology announced a new collaboration with high-tech skincare company Biocogent. The project is focused on developing novel, chemical-free and safe phage-based solutions to target problematic bacteria in the skin microbiome.

Adaptive Phage Therapeutics will be collaborating with Oyster Point Pharma (Nasdaq: OYST) to develop therapies to target multiple opthalmic diseases using APT’s PhageBank™ technology.

Adaptive Phage Therapeutics dosed the first patient in their phase 1/2 study to evaluate their PhageBank™ technology as a treatment for UTIs.